line

Press releases 2009

  • 12/16/2009
    Ad-hoc: Biofrontera AG closes placement of capital increase

  • 12/2/2009
    Ad-hoc: Phase III data of BF-200 ALA demonstrate superiority against Metvix

  • 11/25/2009
    Database closure in Biofrontera’s phase III trial with BF-200 ALA

  • 11/20/2009
    Ad-hoc: Biofrontera AG determines conditions of the capital increase

  • 10/28/2009
    Biofrontera quadruples shareholder base and increases trading volume

  • 9/25/2009
    Ad-hoc: Biofrontera AG successfully completes capital increase

  • 9/9/2009
    Ad-hoc: Biofrontera AG successfully places capital increase

  • 8/28/2009
    Biofrontera reports half-year financial results for 2009

  • 8/14/2009
    Ad-hoc: Result of the optional offer to exchange the 8%-convertible bond 2005/2010

  • 7/29/2009
    Ad-hoc: Extension of the optional offer for the replacement of Biofrontera’s 8% convertible bond 2005/2010

  • 7/27/2009
    Ad-hoc: Clinical study with BF-derm1 shows efficacy in severe chronic urticaria

  • 7/24/2009
    Ad-hoc: Biofrontera AG decides to increase its base capital

  • 7/23/2009
    Ad-hoc: Holders of the 8% convertible bond 2005/2010 of Biofrontera agree with modifications of the bond conditions

  • 7/2/2009
    Ad-hoc: Decisions of the bond holder meeting of Biofrontera’s 8% convertible bond 2005/2010

  • 6/29/2009
    Ad-hoc: Biofrontera AG offers optional replacement and restructuring of the 8% convertible bond 2005/2010

  • 6/9/2009
    Ad-hoc: Biofrontera creates option bond / planned restructuring of the 8% convertible bond 2005/2010

  • 5/28/2009
    Biofrontera raised 3 Million Euro in capital round

  • 5/7/2009
    Ad-hoc: Biofrontera AG places capital increase

  • 4/30/2009
    Biofrontera AG veröffentlicht Geschäftszahlen für 2007

  • 4/29/2009
    Excellent Phase III results of Biofrontera’s BF-200 ALA presented at dermatology congress

  • 4/27/2009
    Biofrontera AG obtains SME status from the EMEA

  • 4/8/2009
    Grünenthal Pharma produces for Biofrontera

  • 2/24/2009
    Ad-hoc: Conversion of Biofrontera bonds

  • 1/29/2009
    Patient recruitment in Biofrontera’s international phase III study with BF-200 ALA completed

  • 1/14/2009
    Ad-hoc: Placement of a capital increase from authorized capital

line2